Monoclonal Antibody 2C5-Modified Mixed Dendrimer Micelles for Tumor-Targeted Codelivery of Chemotherapeutics and siRNA

Pan, Jiayi; Attia, Snir; Subhan, Abdus; Filipczak, Nina; Mendes, Lívia Palmerston; Li, Xiang; Yalamarty, Satya Siva Kishan; Torchilin, Vladimir P.

doi:10.1021/acs.molpharmaceut.0c00075

Cited by 34 publications

(20 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most frequently used synthetic polymers for TO delivery contain but are not limited to polyethylenimine (PEI), poly( l -lysine) (PLL), poly(β‐amino ester) (PβAE), polyamidoamine (PAMAM) dendrimers ( Fig. 3 b) [ [187] , [188] , [189] , [190] , [191] , [192] , [193] , [194] , [195] ]. One common feature of these polymers is that they all contain primary or tertiary amino groups that are protonable.…”

Section: Nanoparticles-based Delivery Of Tosmentioning

confidence: 99%

“…It was found that the interactions of electrostatic oligodeoxynucleotide-dendrimer complexes were sensitive to pH as well as the ionic strength, and the maximal interaction occurred at low pH and ionic strength [ 202 ]. PAMAM dendrimers have inner cavities and peripheral functional groups, which that can be modified into physically embedding or covalently conjugate drugs with high curative effect [ 203 ], so as to become a promising platform for the co-delivery of genes and other drugs [ 188 , 204 , 205 ]. In addition, PAMAM dendrimers can be combined with other polymers to approach specific functionalities, such as sustained delivery of TO.…”

Section: Nanoparticles-based Delivery Of Tosmentioning

confidence: 99%

See 1 more Smart Citation

Delivery of therapeutic oligonucleotides in nanoscale

Zhou

Lin

et al. 2022

Bioactive Materials

View full text Add to dashboard Cite

Therapeutic oligonucleotides (TOs) represent one of the most promising drug candidates in the targeted cancer treatment due to their high specificity and capability of modulating cellular pathways that are not readily druggable. However, efficiently delivering of TOs to cancer cellular targets is still the biggest challenge in promoting their clinical translations. Emerging as a significant drug delivery vector, nanoparticles (NPs) can not only protect TOs from nuclease degradation and enhance their tumor accumulation, but also can improve the cell uptake efficiency of TOs as well as the following endosomal escape to increase the therapeutic index. Furthermore, targeted and on-demand drug release of TOs can also be approached to minimize the risk of toxicity towards normal tissues using stimuli-responsive NPs. In the past decades, remarkable progresses have been made on the TOs delivery based on various NPs with specific purposes. In this review, we will first give a brief introduction on the basis of TOs as well as the action mechanisms of several typical TOs, and then describe the obstacles that prevent the clinical translation of TOs, followed by a comprehensive overview of the recent progresses on TOs delivery based on several various types of nanocarriers containing lipid-based nanoparticles, polymeric nanoparticles, gold nanoparticles, porous nanoparticles, DNA/RNA nanoassembly, extracellular vesicles, and imaging-guided drug delivery nanoparticles.

show abstract

Section: Nanoparticles-based Delivery Of Tosmentioning

confidence: 99%

Section: Nanoparticles-based Delivery Of Tosmentioning

confidence: 99%

Delivery of therapeutic oligonucleotides in nanoscale

Zhou

Lin

et al. 2022

Bioactive Materials

View full text Add to dashboard Cite

show abstract

“…The design of targeted siRNA nanoparticles also has the potential to reduce nonspecific uptake in other cell types. Various targeting agents, e.g., the RGD peptide, [ 39,40 ] transferrin, [ 41 ] hyaluronic acid (HA), [ 42,43 ] and antibodies, [ 44,45 ] have been incorporated onto the siRNA nanoparticles to promote siRNA delivery into cancer cells.…”

Section: Barriers For Sirna Delivery To Target Cells For Effective Camentioning

confidence: 99%

Environment‐Responsive Lipid/siRNA Nanoparticles for Cancer Therapy

Lü

Laney

Hall

et al. 2020

Adv Healthcare Materials

View full text Add to dashboard Cite

RNA interference (RNAi) is a promising technology to regulate oncogenes for treating cancer. The primary limitation of siRNA for clinical application is the safe and efficacious delivery of therapeutic siRNA into target cells. Lipid‐based delivery systems are developed to protect siRNA during the delivery process and to facilitate intracellular uptake. There is a significant progress in lipid nanoparticle systems that utilize cationic and protonatable amino lipid systems to deliver siRNA to tumors. Among these lipids, environment‐responsive lipids are a class of novel lipid delivery systems that are capable of responding to the environment changes during the delivery process and demonstrate great promise for clinical translation for siRNA therapeutics. Protonatable or ionizable amino lipids and switchable lipids as well as pH‐sensitive multifunctional amino lipids are the presentative environment‐responsive lipids for siRNA delivery. These lipids are able to respond to environmental changes during the delivery process to facilitate efficient cytosolic siRNA delivery. Environment‐responsive lipid/siRNA nanoparticles (ERLNP) are developed with the lipids and are tested for efficient delivery of therapeutic siRNA into the cytoplasm of cancer cells to silence target genes for cancer treatment in preclinical development. This review summarizes the recent developments in environment‐response lipids and nanoparticles for siRNA delivery in cancer therapy.

show abstract

“…Consequently, an overexpression of ABC proteins or MRP1 is correlated with the reduced accumulation of chemotherapy drugs in cancer cells. 12 Thus, by inhibiting MRP1 expression, it would be expected that the reduction in the efflux of drugs would help restore intracellular drug levels required to induce apoptosis or cytotoxicity.…”

Section: Introductionmentioning

confidence: 99%